US33938J1060

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results

, 0

BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020. Published on : http://www.globenewswire.com/news-release/2021/01/13/2157753/0/en/Flexion-Therapeutics-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2020-Results.html…

More

Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

, 0

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fireside chat is scheduled to begin at 10:45 a.m. ET on Thursday, January 14, 2021. Published on : http://www.globenewswire.com/news-release/2021/01/07/2155258/0/en/Flexion-Therapeutics-to-Present-at-the-ICR-Westwicke-Investment-Conference.html…

More